Spectral Diagnostics (OTCMKTS:EDTXF) Issues Quarterly Earnings Results

Spectral Diagnostics (OTCMKTS:EDTXF) posted its quarterly earnings results on Friday. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.07), Zacks reports. The business had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.54 million.

Spectral Diagnostics Trading Down 0.2%

Shares of OTCMKTS:EDTXF traded down $0.00 during midday trading on Friday, reaching $1.02. 210 shares of the company were exchanged, compared to its average volume of 16,827. The business’s fifty day moving average is $1.09 and its two-hundred day moving average is $0.80. Spectral Diagnostics has a one year low of $0.32 and a one year high of $1.31. The stock has a market cap of $294.36 million, a PE ratio of -16.97 and a beta of 0.10.

About Spectral Diagnostics

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream.